These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 8903478)

  • 1. Pre-clinical development of the anti-tumour agent CB 7646, bis N-(hydroxymethyl) trimethylmelamine, a stable analogue of trimelamol.
    Coley HM; Jarman M; Brooks N; Kubota T; Goddard PM; Jones M; Lee N; Owens MD; Halbert GW; Judson IR
    Int J Cancer; 1996 Nov; 68(3):356-63. PubMed ID: 8903478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The activity of N-(hydroxymethyl) melamines in fresh human ovarian tumour cells and xenografts.
    Coley HM; Jarman M; Jones M; Sargent JM; Kubota T; Lee NC; Goddard PM; Elgie AW; Williamson C; Taylor CG; Judson IR
    Anticancer Res; 1996; 16(4A):1851-5. PubMed ID: 8712712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stable analogues of the antitumour agent trimelamol retain in vitro cytotoxicity in drug-sensitive and resistant rodent and human cell lines.
    Coley HM; Jarman M; Brooks N; Thornton TJ; Judson IR
    Eur J Cancer; 1994; 30A(12):1827-36. PubMed ID: 7880614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-(Hydroxymethyl) melamines.
    Coley HM
    Gen Pharmacol; 1997 Feb; 28(2):177-82. PubMed ID: 9013191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
    Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation.
    Rutty CJ; Judson IR; Abel G; Goddard PM; Newell DR; Harrap KR
    Cancer Chemother Pharmacol; 1986; 17(3):251-8. PubMed ID: 3091280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the N-(hydroxymethyl)melamines as antitumour agents: mechanism of action studies.
    Coley HM; Brooks N; Phillips DH; Hewer A; Jenkins TC; Jarman M; Judson IR
    Biochem Pharmacol; 1995 May; 49(9):1203-12. PubMed ID: 7763301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and cytotoxicity of potential tumor-inhibitory analogues of trimelamol (2,4,6-tris[(hydroxymethyl)methylamino]-1,3,5-triazine) having electron-withdrawing groups in place of methyl.
    Jarman M; Coley HM; Judson IR; Thornton TJ; Wilman DE; Abel G; Rutty CJ
    J Med Chem; 1993 Dec; 36(26):4195-200. PubMed ID: 8277501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts.
    Goddard P; Valenti M; Kelland LR
    Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cucurbit[7]uril encapsulated cisplatin overcomes cisplatin resistance via a pharmacokinetic effect.
    Plumb JA; Venugopal B; Oun R; Gomez-Roman N; Kawazoe Y; Venkataramanan NS; Wheate NJ
    Metallomics; 2012 Jun; 4(6):561-7. PubMed ID: 22610518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a parenteral formulation of trimelamol, a synthetic S-triazine carbinolamine-containing cytotoxic agent.
    Gibson M; Denham AJ; Taylor PM; Payne NI
    J Parenter Sci Technol; 1990; 44(6):306-13. PubMed ID: 2277318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines.
    Manetta A; Gamboa G; Nasseri A; Podnos YD; Emma D; Dorion G; Rawlings L; Carpenter PM; Bustamante A; Patel J; Rideout D
    Gynecol Oncol; 1996 Feb; 60(2):203-12. PubMed ID: 8631539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
    McKeage MJ; Kelland LR; Boxall FE; Valenti MR; Jones M; Goddard PM; Gwynne J; Harrap KR
    Cancer Res; 1994 Aug; 54(15):4118-22. PubMed ID: 8033145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts.
    Boven E; Nauta MM; Schlüper HM; Erkelens CA; Pinedo HM
    Cancer Chemother Pharmacol; 1986; 18(2):124-8. PubMed ID: 3098444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
    Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
    Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the stability of trimelamol, a carbinolamine-containing antitumor drug.
    Jackson C; Crabb TA; Gibson M; Godfrey R; Saunders R; Thurston DE
    J Pharm Sci; 1991 Mar; 80(3):245-51. PubMed ID: 2051341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel bis-platinum complexes endowed with an improved pharmacological profile.
    Gatti L; Perego P; Leone R; Apostoli P; Carenini N; Corna E; Allievi C; Bastrup U; De Munari S; Di Giovine S; Nicoli P; Grugni M; Natangelo M; Pardi G; Pezzoni G; Singer JW; Zunino F
    Mol Pharm; 2010 Feb; 7(1):207-16. PubMed ID: 19919086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low central nervous system penetration of N2,N4,N6,-trihydroxymethyl-N2,N4,N6,-trimethylmelamine (Trimelamol): a cytotoxic s-triazine with reduced neurotoxicity.
    Judson IR; Rutty CJ; Abel G; Graham MA
    Br J Cancer; 1986 May; 53(5):601-6. PubMed ID: 3087399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical pharmacology and antitumour activity of the novel sequence-selective DNA minor-groove cross-linking agent DSB-120.
    Walton MI; Goddard P; Kelland LR; Thurston DE; Harrap KR
    Cancer Chemother Pharmacol; 1996; 38(5):431-8. PubMed ID: 8765436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.